Results 171 to 180 of about 6,340 (200)
Some of the next articles are maybe not open access.
Obeticholic Acid: First Global Approval
Drugs, 2016Obeticholic acid (Ocaliva(TM)) is a farnesoid-X receptor (FXR) agonist that is being developed by Intercept Pharmaceuticals for the treatment of various liver diseases, and has recently been granted accelerated approval in the USA for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults with an inadequate ...
A, Markham, Susan J, Keam
openaire +2 more sources
Obeticholic acid treatment of mice to promote fertilization and reproduction
Zygote, 2023SummaryObeticholic acid (OCA), a farnesoid X receptor (FXR) agonist, has been demonstrated to ameliorate the histopathological characteristics of liver damage. Nonetheless, the systemic safety profile of OCA with regard to reproduction and development remains poorly understood.
Ming Liang +3 more
openaire +2 more sources
Obeticholic acid in primary biliary cholangitis
Clinics and Research in Hepatology and Gastroenterology, 2017In a double-blind, randomized, placebo-controlled study including 217 patients with primary biliary cholangitis, the authors show that obeticholic acid (a potent farnesoid X agonist) administered with ursodeoxycholic acid or as monotherapy significantly decreases serum alkaline phosphatase and bilirubin when compared to placebo.
openaire +2 more sources
Obeticholic acid in primary biliary cholangitis
Current Opinion in Gastroenterology, 2019This review will summarize the use of obeticholic acid (OCA) in treatment of primary biliary cholangitis (PBC). It seeks to discuss the mechanism of action, evidence for use, appropriate clinical use, and common adverse effects of OCA.PBC is a chronic, progressive cholestatic liver disease that is a chronic progressive that may lead to end-stage liver ...
Vignan, Manne, Kris V, Kowdley
openaire +2 more sources
Obeticholic acid for the treatment of primary biliary cirrhosis
Expert Review of Gastroenterology & Hepatology, 2016There is significant unmet need in Primary Biliary Cholangitis (PBC) in patients under-responsive to the only approved therapy Ursodeoxycholic Acid (UDCA) who are at increased risk of progressing to end-stage liver disease. Obeticholic Acid (OCA) is a farnesoid X receptor (FXR) agonist which has been evaluated as a second line therapy in PBC and has ...
openaire +3 more sources
Obeticholic acid and budesonide for the treatment of primary biliary cirrhosis
Expert Opinion on Pharmacotherapy, 2014Primary biliary cirrhosis (PBC) is a chronic cholestatic liver disease of adults. Treatments are needed when patients have incomplete response to ursodeoxycholic acid (UDCA).Discoveries of the key role played by bile acids (BAs) and nuclear receptors (NRs) in regulating liver and metabolic homeostasis have led to promising therapeutic approaches in ...
Marina G, Silveira, Keith D, Lindor
openaire +2 more sources
The synthesis of fluorinated obeticholic acid derivatives [PDF]
, 2021 Bile acids are steroids found naturally within the bile of humans and other vertebrates. Their physiological roles involve the solubilisation of dietary lipids, lipophilic vitamins and drugs and also the regulation of hepatic cholesterol levels. Additionally, in recent years, bile acids have been found to act as an agonist of receptors such as the FXR ...
openaire
Obeticholic acid for the treatment of primary biliary cirrhosis
Expert Opinion on Orphan Drugs, 2014Introduction: Primary biliary cirrhosis (PBC) is a rare autoimmune liver disease, in which the epithelial cells of small bile ducts are targeted for immune attack leading to cholestasis and cirrhos...
Kidist K Yimam, Christopher L Bowlus
openaire +1 more source
Obeticholic acid for the treatment of hepatobiliary disorders
New St. Petersburg Medical RecordsObeticholic acid is the first-in-class selective farnesoid X receptor agonist that is approved in several countries (since August 2024, including Russia) for the treatment of primary biliary cholangitis in patients with inadequate response to monotherapy with ursodeoxycholic acid or intolerance thereof.
V. A. Prikhodko +2 more
openaire +1 more source